Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Cefiderocol is a novel siderophore cephalosporin antibiotic.
• It targets bacterial iron transport systems for enhanced cellular entry.
• Demonstrates broad in vitro activity against challenging gram-negative pathogens, including multidrug-resistant (MDR) strains.

Purpose of the Study:

• To review in vitro and clinical data on cefiderocol.
• To evaluate its efficacy against MDR gram-negative bacteria.
• To discuss cefiderocol's role in treating complex infections.

Main Methods:

• Review of in vitro susceptibility data.
• Analysis of clinical trial results, including APEKS-NP and CREDIBLE-CR.
• Synthesis of evidence for treatment of complicated urinary tract infections and nosocomial pneumonia.

Main Results:

• Cefiderocol exhibits broad-spectrum activity against MDR gram-negative bacteria.
• Clinical trials demonstrated noninferiority to existing treatments for specific infections.
• Established efficacy in treating complicated urinary tract infections and nosocomial pneumonia.

Conclusions:

• Cefiderocol is a valuable therapeutic option against MDR gram-negative infections.
• Its unique mechanism of action aids in overcoming resistance.
• Supports its use in the clinician's armamentarium for challenging infections.